[en] Injection of substance P (SP) in a rat hindpaw induced extravasation of 125I-labelled albumin in both hindpaws and salivation. Intravenous injection of SP dose-dependently increased vascular permeability. This latter effect was increased in rat paws by captopril, an inhibitor of angiotensin-converting enzyme (ACE), administered locally in combination with diprotin A, an inhibitor of an dipeptidyl(amino)peptidase IV (DAP IV) or phosphoramidon, an inhibitor of neutral endopeptidase (NEP). The increase in permeability induced by SP was inhibited by RP 67580, a NK-1-receptor antagonist. Intravenous injection of capsaicin induced labelled albumin extravasation in rat paws. This effect was increased by combination of captopril with diprotin A or phosphoramidon, but not by captopril associated with amastatin, an inhibitor of aminopeptidase M (AmM). It was suppressed by RP 67580. Injection of collagenase in rat paws triggered a swelling and a local plasma exudation. These responses were reduced by RP 67580 but not by RP 68651, its inactive enantiomer. They were increased by combination of captopril with diprotin A or phosphoramidon in normal rats. The potentiating effects of captopril and diprotin A were suppressed by RP 67580 in normal rats but did not develop in kininogen-deficient rats. The oedema induced by collagenase was also increased by lisinopril, another ACE inhibitor, administered locally in combination with apstatin, an inhibitor of aminopeptidase P (AmP). In rats pretreated by methysergide, collagenase-induced oedema was reduced and can be increased by captopril, by lisinopril, administered alone or by lisinopril associated with apstatin. It is concluded that SP is mainly inactivated in rat paws by ACE, DAP IV and NEP. In collagenase-induced oedema, a low amount of SP would be released from afferent nerve terminals by bradykinin formed in low amounts. Bradykinin is inactivated in rat paws by ACE and AmP. In collagenase-oedema, the pro-inflammatory effects of bradykinin are concealed by the effects of the other mediators.
Disciplines :
Pharmacy, pharmacology & toxicology
Author, co-author :
Damas, Jacques ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques
Bourdon, V.
Liégeois, Jean-François ; Université de Liège - ULiège > Département de pharmacie > Chimie pharmaceutique
Simmons, W. H.
Language :
English
Title :
Influence of Several Peptidase Inhibitors on the Pro-Inflammatory Effects of Substance P, Capsaicin and Collagenase
Boura ALA, Svolmanis AP (1984) Converting enzyme inhibition in the rat by captopril is accompanied by potentiation of carrageenin-induced inflammation. Br J Pharmacol 82:3-8
Damas J (1995) Thermolytic salivation, substance P and kinins in rats. Arch Physiol Biochem 103:476-483
Damas J (1996) The brown Norway rats and the kinin system: a review. Peptides (in press)
Damas J, Adam A (1980) Congenital deficiency in plasma kallikrein and kininogens in the Brown Norway rat. Experientia 36:586-587
Damas J, Remacle-Volon G, Adam A (1984) Inflammation in the rat paw due to urate crystals. Involvement of the kinin system, Naunyn-Schmiedeberg's Arch Pharmacol 325:76-79
Damas J, Liégeois JF, Simmons WH (1996) Potentiation of the proinflammatory effects of bradykinin by inhibition of angiotensin-converting enzyme and aminopeptidase P in rat paws. Naunyn-Schmiedeberg's Arch Pharmacol 354:670-676
Erdös EG, Skidgel RA (1989) Neutral endopeptidase 24,11 (enkephalinase) and related regulators of peptide hormones. FASEB J 3:145-151
Ferreira SH, Moncada S, Parsons M, Vane JR (1975) The concomitant release of bradykinin and prostaglandin in the inflammatory response to carrageenan. Br J Pharinacol 52:108-109
Gamse R, Holzer P, Lembeck F (1980) Decrease of substance P in primary afferent neurones and impairment of neurogenic plasma extravasation by capsaicin. Br J Pharmacol 68:207-213
Gao XP, Rubinstein I (1995) Neutral endopeptidase modulates substance P-induced vasodilation in vivo. J Appl Physiol 78:562-568
Garcia Lerne J (1978) Bradykinin system. In: Vane JR, Ferreira SH (eds) Inflammation. Handbook of experimental pharmacology, vol 50/1. Springer, New York Berlin Heidelberg, pp. 464-522
Garret C, Carruette A, Fardin V, Moussaoui S, Peyronel JF, Blanchard JC, Laduron P (1991) Pharmacological properties of a potent and selective nonpeptide substance P antagonist. Proc Natl Acad Sci USA 88:10208-10212
Holzer P (1991) Capsaicin: cell targets, mechanisms of actions and selectivity for thin sensory neurons. Pharmacol Rev 43:143-201
Kato T, Nagatsu T, Fukasawa K, Harada M, Nagatsu I, Sakakibara S (1978) Successive cleavage of N-terminal Arg1-Pro2 and Lys3-Pro4 from substance P but no release of Arg1-Pro2 from bradykinin by X-Pro dipeptidyl-aminopeptidase. Biochem Biophys Acta 525:417-422
Kitamura S, Carbini LA, Carretero OA, Simmons WH, Scicli AG (1995) Potentiation by aminopeptidase P of blood pressure response to bradykinin. Br J Pharmacol 114:6-7
Legat FJ, Griesbacher T, Lembeck F (1993) Bradykinin is the main mediator of collagenase-induced oedema in the rat paw. Br J Pharinacol 108:57P
Legat FJ, Griesbacher T, Lembeck F (1994) Mediation by bradykinin of rat paw oedema induced by collagenase from Clostridium histlyticum. Br J Pharmacol 112:453-460
Lembeck F, Holzer P (1979) Substance P as neurogenic mediator of antidromic vasodilatation and neurogenic plasma extravasation. Naunyn-Schmiedeberg's Arch Pharmacol 310:175-183
Lembeck F, Griesbacher T, Eckardt M (1990) Demonstration of extra-pulmonary activity of angiotensin converting enzyme in intact tissue preparations. Br J Phannacol 100:49-54
Lindgren BR, Anderson CD, Andersson RGG (1987) Potentiation of inflammatory reactions in guinea-pig skin by an angiotensin converting enzyme inhibitor (MK 422). Eur J Pharmacol 135:383-387
Lynn B, Ye W, Cotsell B (1992) The actions of capsaicin applied topically to the skin of the rat on C-fibre afferents, antidromic vasodilatation and substance P levels. Br J Pharmacol 107:400-406
Maggio JE (1988) Tachykinins. Ann Rev Neurosci 11:13-28
Moussaoui SM, Montier F, Carruette A, Blanchard JC, Laduron PM, Garret C (1993) A non-peptide NK1-receptor antagonist, RP 67580, inhibits neurogenic inflammation postsynaptically. Br J Pharmacol 109:259-264
Prechel MM, Orawski AT, Maggiora LL, Simmons WH (1995) Effect of a new aminopeptidase P inhibitor, apstatin, on bradykinin degradation in the rat lung. J Pharmacol Exp Ther 275:1136-1147
Regoli D, Boudon A, Fauchère JL (1994) Receptors and antagonists for substance P and related peptides. Pharmacol Rev 46:551-599
Roques BP, Noble F, Daugé V, Fournié-Zaluski MC, Beaumont A (1993) Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev 45:87-146
Saria A, Lundberg JM, Skofitsch G, Lembeck F (1983) Vascular protein leakage in various tissues induced by substance P, capsaicin, bradykinin, serotonin, histamine and by antigen challenge. Naunyn-Schmiedeberg's Arch Pharmacol 324:212-218
Skidgel RA (1992) Bradykinin-degrading enzymes: structure, function, distribution, and potential roles in cardiovascular pharmacology. J Cardiov Pharmacol 20:[Suppl 9] S4-S9
Skidgel RA, Engelbrecht S, Johnson AR, Erdös EG (1984) Hydrolysis of substance P and neurotensine by converting enzyme and neutral endopeptidase. Peptides 5:769-776
Souza Pinto JC, Remacle-Volon G, Sampaio CAM, Damas J (1995) Collagenase-induced oedema in the rat paw and the kinin system. Eur J Pharmacol 274:101-107
Theriault E, Otsuka M, Jessel T (1979) Capsaicin evoked release of substance P from primary sensory neurones. Brain Res 67:387-403
Wang L, Ahmad S, Benter IF, Chow A, Mizutani S, Ward P (1991) Differential processing of substance P and Neurokinin A by plasma dipeptidyl(amino) peptidase IV, aminopeptidase M and angiotensin converting enzyme. Peptides 12:1357-1364
